Showing results (511-520 of 529) with videos related to
Sort By:
Pageof 53
Leukemia|December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORW-J Chng, H Goldschmidt, M A Dimopoulos, et al.Leukemia|August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyP Moreau, D Joshua, W-J Chng, et al.Leukemia|November 2, 2013
International Myeloma Working Group recommendations for global myeloma careH Ludwig, J S Miguel, M A Dimopoulos, et al.Nature Genetics|December 3, 2003
Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosisGeorge Papanikolaou, Mark E Samuels, Erwin H Ludwig, et al.Leukemia|April 23, 2010
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementR A Kyle, B G M Durie, S V Rajkumar, et al.Leukemia|July 21, 2006
International uniform response criteria for multiple myelomaB G M Durie, J-L Harousseau, J S Miguel, et al.Leukemia|July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)R Hájek, T Masszi, M T Petrucci, et al.Leukemia|November 21, 2008
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersA Dispenzieri, R Kyle, G Merlini, et al.Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2025
European Myeloma Network Group review and consensus statement on primary plasma cell leukemiaP Musto, M Engelhardt, N W C J van de Donk, et al.Pageof 53